Alerta

CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT

Resumen de: MX2025003937A

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Resumen de: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.

SARS-COV-2 SUBUNIT VACCINE

Resumen de: US2024316183A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the S1 subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

Oligopeptide derivative based on novel coronavirus spike protein SIM site and application thereof

Resumen de: CN120209158A

The invention discloses an oligopeptide derivative based on a novel coronavirus spike protein SIM site and application of the oligopeptide derivative. The oligopeptide derivative disclosed by the invention is an oligopeptide derivative which comprises cpSIM1, cpSIM1 ', cpSIM2, cpSIM3 and cpSIM4, and the oligopeptide derivative is composed of a cell-penetrating peptide and an oligopeptide; the oligopeptides are oligopeptides obtained by modifying related sites of SIM1, SIM1 ', SIM2, SIM3 and SIM4 on the basis of SARS-CoV-2Spike protein polypeptide SUMO; the cell-penetrating peptide is connected to the N terminal of the oligopeptide. The four short peptide derivatives of the cpSIM1, the cpSIM1 ', the cpSIM3 and the cpSIM4 do not influence the cell activity, have no cytotoxicity, and can promote the expression of the SARS-CoV-2Spike protein on the cell surface and enhance the immunogenicity. The cpSIM2 has high specificity for resisting SARS-CoV-2 infection, the effectiveness of the cpSIM2 is verified in in-vivo and in-vitro models, and the cpSIM2 can be used for preparing drugs for resisting different SARS-CoV-2 mutant strain infection and has important application value for targeted therapy of SARS-CoV-2.

BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS

Resumen de: WO2025137284A2

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

RESPIRATORY TRACT INFECTION THERAPEUTICS AGAINST COVID-19

Resumen de: US2025207140A1

Provided herein, inter alia, are compositions comprising nucleic acid compounds and methods of using the compositions for the prevention and treatment of respiratory diseases, including SARS-CoV-2 infections.

METHODS AND COMPOSITIONS FOR INHIBITING VIRAL METHYLTRANSFERASES

Resumen de: US2025205178A1

SARS-CoV-2 has caused a global pandemic with significant humanity and economic loss since the beginning of 2020. Flaviviruses such as Zika and Dengue viruses are also significant human pathogens. Although SARS-CoV-2 vaccines are effective in preventing severe disease outcomes, they are less effective in controlling infection or re-infection, particularly due to rapid evolution of viral variants of SARS-CoV-2. Currently only limited options are available to treat SARS-CoV-2 and flavivirus infections for vulnerable populations. Potential of a future pandemic of other viruses is high. The present invention features compositions and methods for a universal high throughput screening (HTS) assay to identify inhibitors targeting the S-adenosyl-L-methionine (SAM)-binding site of viral methyltransferases (MTases) using SAM as a methyl donor.

PAN-CHEMOKINE ANTAGONISTS FOR USE IN TREATING CANCER AND IMMUNE DISORDERS

Resumen de: US2025206754A1

A chemical compound 2-({6-phenylthieno2,3-dpyrimidin-4-yl}oxy)benzamide for use as a CCR7 (C-C chemokine receptor type 7) antagonist. It is also a pan-chemokine antagonist and has an antagonistic effect to CCR1, CCR2, CCR3, CCR5, CCR9 and CXCR4 chemokine receptors for use in the prevention of metastatsis formation in lung, liver and ribs in in vivo mice breast cancer model. Also described are chemical compounds 3-chloro-2-{6-(2-chlorophenyl)-2,5-dimethylthieno2,3-dpyrimidin-4-yloxy}benzamide and 3-chloro-2-{6-(2-chlorophenyl)-2-methylthieno2,3-dpyrimidin-4-yloxy}benzamide, as pan-chemokine antagonists. These compounds are for use in the prevention or treatment of: (i) diseases associated with chemokine receiptors which are, specifically, lung, liver, ribs and lymph node metastasis and the progression of many different malignancies such as breast, gastric, skin (melanoma), head and neck, lung, esophageal, hepatocellular, cervical, thyroid, tonsillar, colorectal and prostate cancers; (ii) virus infection diseases associated with chemokine receptors such as HIV-1, HIV-2, SARS-CoV-2 (COVID-19); and (iii) the immune related diseases such as psoriasis, arthritis and atopic demiatitis.

TREATMENT OF VIRUSES WITH ANTIVIRAL NUCLEOSIDES

Resumen de: US2025205268A1

Therapies comprising administering at least one antiviral nucleoside, and the use of such therapies in the treatment of viral infections, such as infection by Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus, Chikungunya virus, Ross River virus, orthomyxoviridae virus, paramyxoviridae virus, RSV, influenza A virus, influenza B virus, filoviridae virus, human coronavirus, SARS-CoV-1, MERS-CoV, SARS-CoV-2, Ebola virus, or Zika virus, are disclosed herein.

ANTIVIRAL COMPOSITION COMPRISING CHITOSAN AND XANTHOHUMOLONE

Resumen de: US2025205273A1

The present invention relates to a composition comprising at least chitosan and xanthohumolone, to a process for preparing same and to the uses thereof. More particularly, the invention relates to a composition comprising at least chitosan and xanthohumolone for use as an antiviral composition, in particular in the treatment or prevention of COVID-19.

PEPTIDES, NUCLEIC ACIDS, RECOMBINANT EXPRESSION VECTORS, CELLS, SARS-COV-2 VACCINE SUBSTANCE, SARS-COV-2 VACCINE COMPOSITION, AND SARS-COV-2 IMMUNIZATION METHOD

Resumen de: WO2025135605A1

Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.

SHORT VIRAL RNAS (SVRNAS) WITH THERAGNOSTIC POTENTIAL IN INFECTION WITH SARS-COV-2 AND RELATED VIRUSES

Resumen de: WO2025137577A1

Provided herein are short viral RNA (svRNA) and human RNA sequences that exhibit modulated expression during viral infection and are therefore useful for detecting viral infections. Further disclosed herein are compositions, methods, and kits for detecting and treating infections, including early-stage and latent infections with low viral titers. In certain embodiments the compositions, methods, and kits for detecting and treating infections include detecting in a sample from a subject 10-50 nucleotide length short viral RNA (svRNA), modulated expression of 10-50 nucleotide length RNA in the subject, or a combination thereof, thereby detecting infection by a virus in the subject.

T CELL-BASED SARS-COV-2 VACCINE

Resumen de: WO2025137448A1

The present disclosure relates to coronavirus vaccines and methods for use thereof.

SARS-COV-2 SUBUNIT VACCINE

Resumen de: US2025186576A1

The present invention relates to a protein subunit vaccine comprising at least one antigen characterized in that it comprises at least one monomer from at least one variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), wherein the at least one monomer is selected from the group consisting of the SI subunit of the Spike protein or the receptor-binding domain (RBD) of the Spike protein. In an aspect of the present invention, the protein subunit vaccine comprises at least one antigen characterized in that it comprises two monomers from at least one variant of SARS-CoV-2, wherein each of the monomers are selected from the group consisting of the S1 subunit or RBD protein, and wherein the monomers are chemically bound to each other, optionally through a linker, forming fusion dimers or non-fusion dimers. The protein subunit vaccine may further comprise at least an adjuvant and at least an immunostimulant.

Diagnostic testing apparatus and system

Resumen de: GB2636672A

A method and an apparatus utilizing targeted ion mobility spectrometry for the detection of the SARS-CoV-2 virus and its variants, by measuring the quantity of free polyamines including putrescine, spermidine, and spermine in a sublingual saliva sample. Other embodiments are capable of providing instant, cost effective, POC testing and test results for other viral and bacterial infections including influenza, acute and chronic respiratory conditions, certain forms of inflammation, and the detection of certain abnormal cells in human subjects.

2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Resumen de: CR20250205A

The present invention provides a compound of Formula I wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

COMPOSITIONS AND METHODS FOR TREATING POST-COVID CONDITIONS OF FATIGUE

Resumen de: ZA202401786B

Disclosed is a method for treating a subject that has previously been infected with SARS-CoV-2 and exhibiting at least one Post COVID- 19 Conditions of fatigue (PCC of fatigue) symptom. The method comprises administering to the subject a therapeutically effective amount of a composition comprising therapeutic double-stranded RNA (tdsRNA). Compositions, medicaments and delivery systems comprising tdsRNA for the treatment of PCC of fatigue are also disclosed.

BIOMARKERS AND USES THEREOF IN DIAGNOSIS AND TREATMENT OF NEUROLOGICAL POST ACUTE SEQUELAE OF COVID 19 (NPASC)

Nº publicación: EP4573370A1 25/06/2025

Solicitante:

PERCHERON THERAPEUTICS LTD [AU]
Percheron Therapeutics Ltd

Resumen de: AU2023326053A1

Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological sample from the subject. Also disclosed herein are methods for treating a subject identified as having a high likelihood of suffering from NP ASC and treating the subject by modulating the level or activity of an NPASC therapeutic target identified herein.